Long COVID in autoimmune rheumatic diseases

Rheumatol Int. 2023 Jul;43(7):1197-1207. doi: 10.1007/s00296-023-05319-0. Epub 2023 Mar 30.

Abstract

Consequences of Corona Virus Disease-19 (COVID-19) in patients with rheumatic diseases (RDs) are clinically diverse. SARS-CoV-2 infection has been associated with various autoimmune and rheumatic manifestations over the past three years. Emerging evidence points to the possibility of Long COVID predisposition in rheumatic patients due to the changes in immune regulatory response. The aim of this article was to overview data on the pathobiology of Long COVID in patients with RDs. Related risk factors, clinical characteristics, and prognosis of Long COVID in RDs were analyzed. Relevant articles were retrieved from Medline/PubMed, Scopus, and Directory of Open Access Journals (DOAJ). Diverse mechanisms of viral persistence, chronic low-grade inflammation, lasting production of autoantibodies, endotheliopathy, vascular complications, and permanent tissue damage have been described in association with Long COVID. Patients with RDs who survive COVID-19 often experience severe complications due to the immune disbalance resulting in multiple organ damage. Regular monitoring and treatment are warranted in view of the accumulating evidence.

Keywords: Autoimmunity; COVID-19; Long COVID; Post-COVID-19; Rheumatic diseases.

Publication types

  • Review

MeSH terms

  • Autoimmune Diseases* / complications
  • COVID-19* / complications
  • Humans
  • Post-Acute COVID-19 Syndrome
  • Rheumatic Diseases* / drug therapy
  • SARS-CoV-2